Advances in Pharmacogenetics Research of Chemotherapeutic Drugs for Acute Leukemia
A special issue of Biomedicines (ISSN 2227-9059).
Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 174
Special Issue Editor
Interests: pharmacogenetics; pharmacogenomics; precision medicine; acute myeloid leukemia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue, entitled “Advances in Pharmacogenetics Research of Chemotherapeutic Drugs for Acute Leukemia”, will focus on any research that advances the discovery and/or validation of pharmacogenetic markers for their use in the treatment of acute myeloid leukemia (AML). AML remains a difficult-to-treat disease in need of novel and effective therapies. The long-term goal of pharmacogenetic studies is to use genotype data to predict the effective treatment response to a specific drug, in turn preventing potential undesirable effects of its administration. Pharmacogenetic information might be useful for optimizing AML therapy by selecting in each case the most appropriate treatment based on the genetic characteristics of both disease and patient.
We cordially invite authors in the field to submit original research or review articles pertaining to this important and rapidly progressing field of biomedicine.
Dr. Miriam Saiz-Rodrigez
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
